CollPlant Biotechnologies Ltd
CLGN Nasdaq· Orthopedic, Prosthetic & Surgical Appliances & Supplies
Last close · Oct 30, 2026
$4.14
KIRA · Stoqly’s AI analyst, in plain words
- CollPlant Biotechnologies Ltd had only $2.4M of revenue in fiscal 2025: it is still developing what it sells. It spent $8.2M on research and development, 59% of its operating costs.
- Its operating margin was −484.3%, up 2,865.4 pts: of every 100 in sales, about −484 is left after running the business.
- CollPlant Biotechnologies Ltd lost $11.5M in fiscal 2025. With no meaningful sales yet, it pays for its work from the cash it holds.
- Free cash flow was −$9.4M in fiscal 2025, −398.4% of revenue. At that burn of $9.4M a year, its $5.6M of cash and short-term investments would last about 0.6 years.
Market cap
$50.5M
P/E
—
Revenue
$2.4M
Net income
−$11.5M
Free cash flow
−$9.4M
Operating margin
−484.3%
CollPlant Biotechnologies Ltd in 30 seconds · fiscal 2025
Are shareholders being diluted?
+6.5%
Somewhat. The share count rose 6.5% last year, so each share owns a little less.
Does it make a profit?
$8.2M R&D
Not yet: it has no meaningful sales. It spent $8.2M on research and development, 59% of its operating costs.
How long would its cash last?
0.6 yrs
Not long. It burns $9.4M a year and holds $5.6M, under a year at that pace, so it may need new money soon.
How healthy are the accounts?
3 / 8
It passes 3 of 8 health tests, but most of them need sales, so the score says little before revenue starts.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What CollPlant Biotechnologies Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 26, 2026
- Legal name
- CollPlant Biotechnologies Ltd
- CIK
- 0001631487
CollPlant Biotechnologies Ltd · CLGN · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $15.6M | $0.3M | $11.0M | $0.5M | $2.4M |
| Revenue growth | 154.9% | −98.1% | 3,565.2% | −95.3% | 360.4% |
| Gross margin | 87.2% | −33.8% | 81.8% | −215.5% | 64.8% |
| Operating margin | 0.4% | −5,718.1% | −68.5% | −3,349.7% | −484.3% |
| Net income | $0.2M | −$16.9M | −$7.0M | −$16.6M | −$11.5M |
| Net margin | 1.5% | −5,660.5% | −64.0% | −3,225.0% | −484.6% |
| Diluted EPS | $0.02 | −$1.53 | −$0.62 | −$1.45 | −$0.94 |
| Cash | |||||
| Cash from operations | $2.5M | −$13.7M | −$2.8M | −$14.1M | −$9.4M |
| Capital expenditure | $1.4M | $1.3M | $1.0M | $0.5M | $0.0M |
| Free cash flow | $1.1M | −$15.0M | −$3.7M | −$14.6M | −$9.4M |
| FCF margin | 6.9% | −5,007.4% | −33.9% | −2,830.3% | −398.4% |
| Share count change | 73.8% | −7.8% | 3.2% | 0.6% | 6.5% |
| Debt and strength | |||||
| Cash and short-term investments | $13.1M | $29.7M | $26.7M | $11.9M | $5.6M |
| Debt incl. finance leases | $0.2M | $0.3M | — | — | — |
| Shareholders' equity | $45.1M | $32.3M | $28.3M | $13.5M | $6.1M |
| Net debt / EBITDA | −15.4x | — | — | — | — |
| Current ratio | 15.0x | 10.2x | 8.6x | 4.4x | 2.5x |
| Returns and quality | |||||
| Return on capital | 0.2% | −458.0% | — | — | — |
| Return on equity | 1.0% | −43.7% | −23.2% | −79.5% | −117.6% |
| Return on tangible equity | 0.5% | −52.8% | −24.9% | −124.6% | −191.2% |
| Piotroski F-score | 6 | 2 | 4 | 1 | 3 |
| Altman Z'' | 8.5 | 0.4 | −0.8 | −19.7 | −41.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CollPlant Biotechnologies Ltd · CLGN · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.14 a share, the company is worth $50.5M.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001631487). Latest version: stoqly.net/companies/clgn. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.